| Title |
Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, November 2009
|
| DOI | 10.1007/s10549-009-0624-6 |
| Pubmed ID | |
| Authors |
Atanas Ignatov, Tanja Ignatov, Albert Roessner, Serban Dan Costa, Thomas Kalinski |
| Abstract |
Tamoxifen is the most frequently used anti-hormonal drug for treatment of women with hormone-dependent breast cancer. The aim of this study is to investigate the mechanism of tamoxifen resistance and the impact of the new estrogen G-protein coupled receptor (GPR30). MCF-7 cells were continuously exposed to tamoxifen for 6 months to induce resistance to the inhibitory effect of tamoxifen. These tamoxifen-resistant cells (TAM-R) exhibited enhanced sensitivity to 17-ss-estradiol and GPR30 agonist, G1, when compared to the parental cells. In TAM-R cells, tamoxifen was able to stimulate the cell growth and MAPK phosphorylation. These effects were abolished by EGFR inhibitor AG1478, GPR30 anti-sense oligonucleotide, and the selective c-Src inhibitor PP2. Only EGFR basal expression was slightly elevated in the TAM-R cells, whereas GPR30 expression and the basal phosphorylation of Akt and MAPK remained unchanged when compared to the parental cells. Interestingly, estrogen treatment significantly increased GPR30 translocation to the cell surface, which was stronger in TAM-R cells. Continuous treatment of MCF-7 cells with GPR30 agonist G1 mimics the long-term treatment with tamoxifen and increases drastically its agonistic activity. This data suggests the important role of GPR30/EGFR receptor signaling in the development of tamoxifen resistance. The inhibition of this pathway is a valid option to improve anti-hormone response in breast cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 1% |
| Netherlands | 1 | 1% |
| France | 1 | 1% |
| Unknown | 83 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 24% |
| Researcher | 11 | 13% |
| Student > Doctoral Student | 10 | 12% |
| Student > Master | 10 | 12% |
| Student > Bachelor | 7 | 8% |
| Other | 17 | 20% |
| Unknown | 10 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 22 | 26% |
| Biochemistry, Genetics and Molecular Biology | 19 | 22% |
| Medicine and Dentistry | 17 | 20% |
| Chemistry | 5 | 6% |
| Physics and Astronomy | 2 | 2% |
| Other | 9 | 10% |
| Unknown | 12 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2011.
All research outputs
#7,453,827
of 22,787,797 outputs
Outputs from Breast Cancer Research and Treatment
#1,658
of 4,655 outputs
Outputs of similar age
#33,431
of 93,077 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#20
of 49 outputs
Altmetric has tracked 22,787,797 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,655 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 93,077 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.